In-vitro diagnostics and laboratory services company Renalytix plc (NASDAQ:RNLX) (LSE:RENX) announced on Friday Medicare's final coverage determination for its kidney disease test, kidneyintelX.dkd.
The test is approved for patients with type 2 diabetes and early-stage chronic kidney disease, with coverage starting 1 August 2024. The established Medicare price for kidneyintelX.dkd is USD950 per test.
This decision follows FDA authorisation, clinical data, guideline inclusion and broad insurance coverage, paving the way for wider test adoption.
Xylyx Bio receives SBIR grant from NIDDK
Lilly expands manufacturing footprint in Ireland
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lifecare sensor achieves 9-week longevity in dog trial
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Sumitomo Pharma and Poxel report positive results from TWYMEEG study in Japan
Sapphiros names new chief financial officer
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem